TYBR Health
TYBR Health is a Houston-based medical device company that develops the FDA-cleared B3 GEL System, a collagen-based flowable ECM hydrogel used by orthopedic surgeons to prevent post-surgical scar formation and preserve tendon mobility in tendon and soft-tissue repair procedures.
- Company typePrivate
- Founded2020
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TYBR Health does
TYBR Health, Inc. is a Houston, Texas-based private medical device company founded in 2020 that develops and commercializes the FDA-cleared B3 GEL System, a collagen-based flowable extracellular matrix hydrogel paired with a proprietary delivery device intended to protect tendons and ligaments during the critical post-surgical healing window and prevent restrictive scar formation. The technology is designed to conform to irregular tissue surfaces, solidify within 2–3 minutes, maintain tendon gliding mechanics, and naturally degrade over time; it is being positioned across orthopedic soft-tissue procedures including hand, wrist, foot and ankle, knee, and shoulder tendon repairs. The company's revenue model is hardware/medical device sales of the B3 GEL System to orthopedic surgeons and healthcare institutions, with quote-based pricing disclosed only on request and an emerging distributor channel; it has completed only its first U.S. clinical use as of January 2026.
The company is led by co-founder and CEO Timothy Keane and co-founder/CTO P. Alex Smith, with Jeff Tyber (former Tyber Medical CEO) joining the board in January 2026. Strategic research collaborations include the University of Virginia (cadaver validation studies) and NIH-funded preclinical work that produced quantified evidence such as a 7% range-of-motion improvement and 35% reduction in adhesion formation versus controls. Cumulative disclosed funding is approximately $2.3M across seed and follow-on rounds from Asymmetry Ventures, Eight Capital, Y Combinator, Texas A&M Innovation, and MedTech Innovator, alongside an additional ~$1.08M raised in January 2025. Headcount is reported at 1–10 employees and the company is presently operating at a pre-revenue or sub-$1M commercial scale, targeting the ~110,000 annual U.S. tendon procedures market.
TYBR Health firmographics
Firmographics- Name
- TYBR Health
- Legal name
- TYBR Health, Inc.
- Website
- https://tybrhealth.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TYBR Health is a Houston-based medical device company that develops the FDA-cleared B3 GEL System, a collagen-based flowable ECM hydrogel used by orthopedic surgeons to prevent post-surgical scar formation and preserve tendon mobility in tendon and soft-tissue repair procedures.
- Ownership category
- akta.pro rank
TYBR Health industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)
Keywords
Where TYBR Health is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TYBR Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- B3 GEL™ System Medical Device Sales: TYBR Health generates revenue through the sale of its FDA-cleared B3 GEL™ System, which includes a proprietary delivery device and the collagen-based flowable gel consumable. The system is used in orthopedic soft-tissue surgical procedures.
- Clinical Procedure Utilization: Revenue is driven by surgical procedure volume as healthcare providers utilize the B3 GEL™ System during tendon and soft-tissue repair surgeries across multiple procedure types including hand, wrist, knee, and shoulder applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
TYBR Health product offering
Product offeringCore offering
TYBR Health develops and sells the FDA-cleared B3 GEL™ System, a collagen-based decellularized extracellular matrix (ECM) flowable gel paired with a proprietary delivery device, used by orthopedic surgeons during tendon and soft-tissue repair surgeries to create a temporary biomechanical spacer that prevents restrictive scar formation and preserves post-operative mobility. The gel solidifies in 2–3 minutes, is brilliant blue for visual coverage validation, and naturally degrades after supporting the critical healing window.
Product overview
TYBR Health offers a single unified product — the FDA-cleared B3 GEL™ System — which is a proprietary delivery system that mixes and precisely applies a brilliant blue collagen-based flowable gel to protect tendons and ligaments during post-surgical healing. The system is designed for orthopedic soft-tissue procedures and works by creating a temporary biomechanical spacer that maintains tissue separation long enough to promote healthy, independent tissue healing while limiting deleterious inflammatory response.
Differentiator
Problem solved
Functional benefit
Products and services
- B3 GEL™ System The B3 GEL™ System is an FDA-cleared collagen-based flowable gel paired with a proprietary delivery device, designed for orthopedic surgeons to apply during tendon and soft-tissue repair procedures (hand/wrist, foot and ankle, knee, shoulder). The thermally responsive gel conforms to irregular tissue surfaces, solidifies in 2–3 minutes, and provides a temporary biomechanical spacer that prevents restrictive scar formation while supporting natural tissue remodeling. Its brilliant blue color enables surgeons to visually confirm application coverage. The system is sold to hospitals, ambulatory surgery centers, orthopedic practices, and medical device distributors.
Quantifiable outcome
- 7% improvement in range of motion - B3 GEL™ treated tendons achieved 50.4° ROM vs. 34.3° in controls
- +3 more outcomes
Companies that use TYBR Health
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
TYBR Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TYBR Health partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- University of VirginiacoreCollaborative research partnership with University of Virginia for validation studies and cadaver studies. Clinical cadaveric study conducted with UVA & TYBR Health demonstrating biomechanical safety of B3 GEL™ when overloading gliding tissues. Studies confirmed the gel is capable of covering the entire surface of the repair and preserving tendon mobility.
- National Institutes of Health (NIH)coreNIH-funded research supporting the development and validation of B3 GEL™ technology. NIH funding contributed to preclinical research demonstrating the gel's effectiveness in preventing adhesion formation and protecting healing tissues.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
TYBR Health competitors and assessment
Company assessmentBroad incumbents
- Integra LifeSciences: Larger regenerative medicine and surgical device company with collagen-based matrices, dural repair grafts, and wound healing products. Comparable because both companies sell biologic ECM-derived matrices used in surgical healing and soft-tissue protection.
- Organogenesis: Regenerative medicine company producing skin substitutes and wound-healing biologics. Comparable because both companies sell FDA-cleared biologic matrices used to promote healing and prevent complications in surgical and wound care contexts.
- Baxter International: Large medtech company selling surgical sealants and hemostats (Tisseel, FloSeal) used intra-operatively. Comparable because Baxter's surgical adjuncts compete in the same surgical workflow as TYBR's flowable gel for soft-tissue procedures.
- Smith & Nephew: Global orthopedic and wound management company with products spanning soft-tissue repair and post-surgical wound care. Comparable because Smith & Nephew operates across the same orthopedic soft-tissue repair and surgical healing market that TYBR targets.
Direct peers
- MiMedx: Regenerative medicine company selling placental tissue and ECM-based products for surgical and wound healing applications. Comparable because both companies sell biologic ECM-derived matrices positioned for post-surgical soft-tissue protection and healing.
- TELA Bio: Regenerative soft-tissue reconstruction company using biologic matrices in hernia and other soft-tissue repairs. Comparable because both companies apply biologic mesh/matrix technology to improve post-surgical tissue healing outcomes.
- Cohera Medical: Medical device company developing surgical adhesives and internal sealants for soft-tissue procedures. Comparable because Cohera targets the same surgical adjunct opportunity — internal soft-tissue protection and adhesion prevention — using flowable/biodegradable materials.
- Anika Therapeutics: Orthopedic and regenerative medicine company with hyaluronic acid–based products for joint preservation and soft-tissue healing. Comparable because both companies develop injectable/flowable biologics for orthopedic soft-tissue repair.
Emerging players
- Adhezion Biomedical: Medical device company focused on surgical adhesives and sealants for wound closure and soft-tissue applications. Comparable because both companies develop flowable topical/internal adjuncts that compete in surgical soft-tissue healing.
- Polyganics: Medical device company developing bioresorbable polymer- and collagen-based products for peripheral nerve and soft-tissue repair. Comparable because Polyganics targets post-surgical soft-tissue healing with biocompatible materials, similar to TYBR's ECM-based approach.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
TYBR Health social profiles
Digital presenceTYBR Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
TYBR Health leadership team
Management profileNumber of profiles
Profiles3 records
TYBR Health funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TYBR Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TYBR Health
What does TYBR Health do?
TYBR Health develops and sells the FDA-cleared B3 GEL™ System, a collagen-based decellularized extracellular matrix (ECM) flowable gel paired with a proprietary delivery device, used by orthopedic surgeons during tendon and soft-tissue repair surgeries to create a temporary biomechanical spacer that prevents restrictive scar formation and preserves post-operative mobility. The gel solidifies in 2–3 minutes, is brilliant blue for visual coverage validation, and naturally degrades after supporting the critical healing window.
Is TYBR Health a public or private company?
TYBR Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was TYBR Health founded?
TYBR Health was founded in 2020. It employs 1 to 10 people.
Where is TYBR Health based?
TYBR Health is headquartered in Houston, United States, in the North America region.
How does TYBR Health make money?
Two revenue lines are on record. B3 GEL™ System Medical Device Sales are the primary driver. The others are clinical Procedure Utilization.
Who are TYBR Health's main competitors?
Broad incumbents on record are Integra LifeSciences, Organogenesis, Baxter International and Smith & Nephew. Direct peers are MiMedx, TELA Bio, Cohera Medical and Anika Therapeutics. Emerging players are Adhezion Biomedical and Polyganics.
Does TYBR Health have an API?
No public API is recorded for TYBR Health.
What industry is TYBR Health in?
TYBR Health's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 3391 and its SIC code is 3842.